OBT in the News

The annual Thames Valley SME Growth 100 index recognises and promotes the region’s high-growth small and medium-sized enterprises, and is ranked by year on year growth. Independent, privately-owned companies, headquartered in the region, that have grown their turnover significantly in the past year are included. We are pleased that OBT has topped the 2022 index with our substantial growth of 154.5%.

September 14 2022: “Targeting CD205-expressing cells may not only remove cancer cells, but also allow the immune system to reset and restart in an immunogenic direction by selectively depleting regulatory cells, and preventing T cell activation and proliferation. Read more about how OBT is developing a dual action antibody-drug conjugate (ADC), targeting the CD205 protein on a) cancer immune inhibitory cells to reverse immune suppression, and b) the cancer cells directly.

March 18 2021: “If we could understand why some people reengage their immune system after receiving chemotherapy, while others don’t, we could think about how to combine various therapeutic modalities and in what sequence”, says Christian Rohlff, PhD, CEO of Oxford BioTherapeutics. Read more about how OBT uses proprietary immuno-oncology technology and antibody-drug conjugates to develop novel therapeutics that can reengage the immune system to destroy cancer cells.